Clinical trials: Human Immunodeficiency Virus I Infection
HIV Infections
Evaluating a Combination of Immune-based Therapies to Achieve a Remission of HIV Infection
A phase I/IIa, multinational, multicentric (IDIBAPS, IRSICAIXA, AARHUS, VUB, APHP), randomised, balanced by centre (to include participants from the 4 arms), open-label, controlled clinical trial.
- Trial name
- HIVACAR (NCT03619278)
- Testing
- HIVACAR
- Sponsor
- Judit Pich
HIV-1-infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
UB-421 subcutaneous formulation (UB-421 SC) is developed to provide HIV infected patients a more convenient drug delivery method.
- Trial name
- NCT04620291
- Testing
- UB-421 SC
- Volunteers
- 18 people
- Sponsor
- United BioPharma
HIV Infections
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
To assess the safety and tolerance of multiple oral doses of 141W94 alone, in combination with 1592U89, and in combination with Retrovir and Epivir, administered to patients with HIV infection as measured by the development of…
- Trial name
- NCT00002183
- Testing
- Abacavir sulfate, Amprenavir, Lamivudine
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Glaxo Wellcome
Human Immunodeficiency Virus I Infection
An Automated, Tailored Information Application for Medication Health Literacy
The purpose of this study is to evaluate the acceptability and efficacy of a computer-based tailored information application designed to promote health literacy in persons treated for HIV infection.
- Trial name
- NCT01304186
- Testing
- Tailored Information
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Nova Southeastern University
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Infection, Human Immunodeficiency Virus
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
This study will be a phase 1, open label, parallel group, three period crossover study to evaluate the effect of dolutegravir (DTG) on the steady state pharmacokinetics of metformin and on the safety and tolerability of…
- Trial name
- NCT02064374
- Testing
- Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV, Therapeutic Vaccine
Therapeutic Vaccine for HIV
Background: In most people who have human immunodeficiency virus (HIV), the immune system cannot control or cure the infection. Antiretroviral therapy drugs can keep the amount of HIV virus low for a long time.
- Trial name
- NCT01859325
- Testing
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
The purpose of this study is to evaluate the safety and the feasibility, and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations (Ttn and HSPCtn) in patients with HIV-1-related…
- Trial name
- GENHIV (NCT03593187)
- Testing
- Cal-1 (LVsh5/C46) drug product
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infection, Human Immunodeficiency Virus I, HIV Infection
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.
- Trial name
- ASSERT (NCT00549198)
- Testing
- Abacavir/lamivudine and efavirenz, Tenofovir/Emtricitabine and efavirenz
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 392 people
- Sponsor
- GlaxoSmithKline
Latent Tuberculosis
Tuberculosis Clinical Trials Consortium Study 35
Hypotheses: Rifapentine (given as water-dispersible monolayer and/or fixed dose combination with isoniazid) dosing in HIV-infected and uninfected children ≤ 12 years of age with latent TB infection (LTBI) or with exposure to…
- Trial name
- NCT03730181
- Testing
- Rifapentine, Isoniazid
- Where
- South Africa
- Volunteers
- 69 people
- Sponsor
- Centers for Disease Control and Prevention
Infection, Human Immunodeficiency Virus
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5 days (Treatment A) followed by a washout period. In Period 2, subjects will receive GSK2248761 200mg once daily for 5 days (Treatment B).
- Trial name
- NCT01101893
- Testing
- Raltegravir, GSK2248761, GSK2248761 + Raltegravir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of…
- Trial name
- NCT01263015
- Testing
- Dolutegravir, Atripla, Abacavir/Lamivudine
- Where
- 145 sites in United States, Australia and 10 more
- Volunteers
- 844 people
- Sponsor
- ViiV Healthcare
HIV Infections, HIV Seronegativity
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
AMENDED 8/94: To expand the safety and immunogenicity profile of MN rgp160 vaccine (Immuno-AG) by administering a higher dose (800 mcg) at 0, 1, 6, and 12 months and 0, 2, 8 and 14 months (these two schedules were compared in VEU…
- Trial name
- NCT00001043
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
To determine the safety profile, assess pharmacokinetic properties (blood levels), and obtain preliminary indication of the antiviral and immunologic effects of recombinant CD4 immunoglobulin G (CD4-IgG).
- Trial name
- NCT00000663
- Testing
- CD4-IgG
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus I Infection
MMF for HIV Reservoir Reduction
This is an open label, randomized Phase II study to determine whether Mycophenolate mofetil (MMF) given over 22 months meaningfully decreases the size of participants' HIV reservoir.
- Trial name
- NCT03262441
- Testing
- Mycophenolate Mofetil 500Mg Tab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Hiv, HIV I Infection
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals.
- Trial name
- NCT06805656
- Testing
- Maraviroc, Dolutegravir, Dendritic Cell Vaccine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo
HIV Infections
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Despite risk reduction counseling, some individuals in HIV vaccine trials or vaccine preparedness studies may engage in risk behavior that results in HIV infection.
- Trial name
- NCT00029913
- Testing
- Observation
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 54 people
- Sponsor
- HIV Vaccine Trials Network
HIV Coinfection, Aids/Hiv Problem
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the…
- Conditions
- HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus
- Trial name
- MSPB_TB (NCT05065905)
- Testing
- Interferon-Gamma
- Where
- 2 sites in Russia
- Volunteers
- 78 people
- Sponsor
- SPP Pharmaclon Ltd.
HIV -1 Infection
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and…
- Trial name
- NCT07698600
- Testing
- BNT168
- Where
- 4 sites in United States, South Africa
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Human Immunodeficiency Virus-Type 1
A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
The purpose of this study is to assess the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type I (HIV-1) infection among Filipino adults.
- Trial name
- NCT01726348
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica